Form 4: Myriad Genetics: Chief Accounting Officer Natalie Munk Reports Stock Transactions
SEC Form 4 Filing
Natalie Munk, Chief Accounting Officer of Myriad Genetics, reports acquisition and disposal of company stock related to restricted stock units.
Summary
- On March 13, 2025, Natalie Munk, Chief Accounting Officer of Myriad Genetics, acquired 4,000 shares of common stock as restricted stock units at $0.
- On March 14 and 15, 2025, she disposed of 855 and 684 shares respectively at $10.07 to cover tax withholding obligations related to vesting restricted stock units.
- Following these transactions, Munk directly owns 49,036 shares of Myriad Genetics common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions, which carries a neutral sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/13/2025 | Acquisition of 4,000 shares of common stock as restricted stock units. |
| 03/14/2025 | Disposal of 855 shares to cover tax withholding obligations at $10.07. |
| 03/15/2025 | Disposal of 684 shares to cover tax withholding obligations at $10.07. |
| 03/17/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.